- Home
- WHF vs ANTX Comparison
WHF vs ANTX Comparison
Compare WHF & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | ANTX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 172.9M |
| IPO Year | 2012 | 2022 |
Fundamental Metrics
Financial Performance| Metric | WHF | ANTX |
|---|---|---|
| Price | $7.40 | $3.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $7.83 | ★ $9.00 |
| AVG Volume (30 Days) | 111.2K | ★ 302.0K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | ★ 14.18% | N/A |
| EPS Growth | 31.91 | ★ 32.56 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $16.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $1.00 |
| 52 Week High | $7.84 | $7.19 |
Technical Indicators
Market Signals| Indicator | WHF | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 23.04 |
| Support Level | $6.85 | $2.87 |
| Resistance Level | $7.58 | $5.21 |
| Average True Range (ATR) | 0.20 | 0.43 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 82.66 | 7.33 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.